Absolute Bioavailability of Reslizumab in Healthy Subjects
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the absolute bioavailability of reslizumab
following administration of a single subcutaneous (sc) dose to healthy non-Japanese
participants
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries